Difference between revisions of "Team:EPFL"

m
Line 38: Line 38:
 
       <div class="container">
 
       <div class="container">
 
         <div class="row row-grid align-items-center">
 
         <div class="row row-grid align-items-center">
           <div class="col-lg-11">
+
           <div class="col-lg-12">
 
             <div class="pr-md-4">
 
             <div class="pr-md-4">
 
               <h3 class="heading h3 text-white">What is CAPOEIRA ?</h3>
 
               <h3 class="heading h3 text-white">What is CAPOEIRA ?</h3>

Revision as of 21:28, 11 October 2018

iGEM EPFL 2018

CAPOEIRA

Cancer Personalized Encapsulin Immunotherapy and Relapse Assay

Learn more about our project

What is CAPOEIRA ?

While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to retaliate!

Find out more

Project Timeline

Detection

First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells.

Vaccine

Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes.

Immune response

This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells.

Follow up

Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA.

Ultimately, CAPOEIRA trains the immune system to retaliate!